Sfoglia per Autore
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol
1998 R. Silvestrini, M.G. Daidone, S. Veneroni, E. Benini, G. Scarfone, F. Zanaboni, A. Villa, M. Presti, S. Danese, G. Bolis
A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy
1999 G. Scarfone, A. Villa, F. Parazzini, C. Sciatta, G. Polverino, G. Bolis
Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer
1999 G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, S. Reina, E. Pirletti
Site of origin of epithelial ovarian cancer: the endometriosis connection
2000 P. Vercellini, G. Scarfone, G. Bolis, G. Stellato, S. Carinelli, P.G. Crosignani
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
2000 C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, C. Mangioni, V. Lucchini, F. Vecchione, G. Bolis, G. Scarfone, F. Zunino
Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel
2001 G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, F. Parazzini
Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer
2001 G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini
Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, A. Villa, F. Parazzini
A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, C. Sciatta, G.P. Polverino, C. Rosa, P. Guarnerio, F. Parazzini
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
2003 J.B. Trimbos, I. Vergote, G. Bolis, J.B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, L. Giurgea, P. Timmers, C. Coens, S. Pecorelli
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
2003 M.S. Aapro1, F.H. van Wijk, G. Bolis, B. Chevallier, M.E.L. van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. Nooij, M. Presti, C. Scarabelli, T.A.W. Splinter, E. Ploch, L.V.A. Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P.G. Harper, C. Madronal, M. Namer, G. Scarfone, J.E.G.M. Stoot, I. Teodorovic, C. Coens, I. Vergote, J.B. Vermorken
Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial
2004 G. Bolis, G. Scarfone, G. Polverino, F. Raspagliesi, S. Tateo, G. Richiardi, M. Melpignano, M. Franchi, G. Mangili, M. Presti, A. Villa, E. Conta, P. Guarnerio, S. Cipriani, F. Parazzini
A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxe/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and IV ovarian cancer (OC)
2006 G. Scarfone, G. Scambia, F. Raspagliesi, G. Mangili, S. Danese, M. Presti, F. Petruzzelli, B. Costa, G. Bolis
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study
2010 G. Bolis, G. Scarfone, F. Raspagliesi, G. Mangili, S. Danese, P. Scollo, D. Lo Russo, A. Villa, P. D. Aimone, G. Scambia
Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only
2012 E. Grossi, S. Noli, G. Scarfone, A. Villa, F. Parazzini, S. Cipriani, G. Bolis
Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers
2013 S. Noli, S. Cipriani, G. Scarfone, A.G. Villa, E. Grossi, E. Monti, P. Vercellini, F. Parazzini
Clear cell and papillary serous endometrial carcinomas : survival in a series of 128 cases
2013 G. Scarfone, R. Secomandi, F. Parazzini, R. Viganò, G. Mangili, L. Frigerio, A. Villa, S. Tateo, E. Ricci, G. Bolis
Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study
2014 G. Scarfone, A. Bergamini, S. Noli, A. Villa, S. Cipriani, G. Taccagni, P. Vigano', M. Candiani, F. Parazzini, G. Mangili
Epidemiology of breast cancer in young women
2015 F. Parazzini, A. Villa, G. Polverino, S. Noli, G. Scarfone
Whole body MRI for systemic staging of breast cancer in pregnant women
2017 F.A. Peccatori, G. Codacci-Pisanelli, M. Del Grande, G. Scarfone, F. Zugni, G. Petralia
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile